Compare WTO & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WTO | PRFX |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.7M |
| IPO Year | 2021 | 2020 |
| Metric | WTO | PRFX |
|---|---|---|
| Price | $0.72 | $0.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 726.3K | 119.8K |
| Earning Date | 01-27-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $34,589,265.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 54.01 | N/A |
| 52 Week Low | $0.55 | $0.61 |
| 52 Week High | $344.60 | $6.65 |
| Indicator | WTO | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 48.33 | 45.58 |
| Support Level | $0.66 | $0.66 |
| Resistance Level | $0.91 | $0.92 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 32.62 | 56.19 |
UTime Ltd is engaged in the design, development, production, sales and brand operation of mobile phones, accessories and related consumer electronics. It also provides Electronics Manufacturing Services (EMS), including Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) services, for renowned brands. The company operates in China and its products are sold globally, including Mexico, Brazil, the United States, and other emerging markets in South Asia and Africa as well as Europe. It has two in-house brands, UTime, known as its middle-to-high end label and targets middle class consumers from emerging markets; as its low- to mid-end brand, is positioned to the grassroots consumers and price-sensitive consumers in emerging markets.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.